Hancock Prospecting Executive Chairman Gina Rinehart reacts during the Lest We Forget sunset tribute on the eve of ANZAC Day at Sydney Opera House in Sydney, Australia, April 24, 2025.... Purchase Licensing Rights, opens new tab Read more
MELBOURNE, June 15 (Reuters) - Australia's wealthiest person, mining baron Gina Rinehart, has taken a stake of more than $1 billion in the record-setting $75 billion SpaceX (SPCX.O), opens new tab IPO, the Wall Street Journal reported on Monday, citing a person familiar with the matter.
Rinehart's company Hancock Prospecting did not confirm the size of its stake in Elon Musk's SpaceX. However, she said in a statement: "This is a significant investment for Hancock, and we are pleased to have received an allocation in what has been an extremely popular and oversubscribed IPO."
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
She praised Musk for having built two of the world's top 10 largest companies.
“We see SpaceX as a rare business: led by a truly exceptional person, technically exceptional and operating in sectors that are crucial, and with long-term potential," said Rinehart, whose wealth was built on iron ore mined by her company, Hancock Prospecting.
Hancock, which is a significant investor in critical minerals projects, aims to work with SpaceX on supplying its mineral needs.
“In the future, we also see the possibility of mutually beneficial arrangements between SpaceX and Hancock Prospecting’s significant critical minerals investments, as demand grows for the materials and infrastructure needed to support advanced technology," Hancock CEO Garry Korte said in the statement.
Hancock is a significant investor in a swathe of rare earths companies including U.S.-based MP Materials, and Rare Earths Americas (REA.A), opens new tab, and Australia's Lynas Rare Earths (LYC.AX), opens new tab, as well as lithium producer Liontown Resources (LTR.AX), opens new tab among many others.
It bulked up its defence, gold and rare-earths holdings in its $3.3 billion U.S. portfolio this year, filings showed last month.
Rinehart's investment in SpaceX was an instant winner. The shares shot up 19% in their debut last Friday, sending the company's value past $2 trillion to make it the sixth-biggest U.S. company as investors jumped at the chance to get a piece of Musk's sprawling empire spanning rockets, satellites and AI.
While commending Musk's entrepreneurial prowess, Rinehart also called him a patriot for slashing U.S. federal jobs through President Donald Trump's Department of Government Efficiency (DOGE).
"SpaceX is yet another clear example of why the world needs more enterprise, more builders and much less bureaucracy," Rinehart said.
Rinehart, too, has become increasingly political, encouraging some of Australia's wealthiest voters to shift support from the country's opposition Liberal-National conservatives to populist, anti-migration party One Nation.
Reporting by Melanie Burton; Editing by Sonali Paul
Our Standards: The Thomson Reuters Trust Principles., opens new tab
SpaceX (SPCX +19.22%) advanced more than 19% on Friday, its first day of trading -- and reached a market value of $2.1 trillion. This immediately puts it in the league of the world's biggest tech companies, such as Apple and Microsoft, in the so-called "trillion-dollar" club. SpaceX set its IPO price at $135, the stock opened at $150, and it closed at more than $160. The IPO offers SpaceX a spot in the record books, as it raised $75 billion for the biggest IPO ever.
It isn't uncommon for a stock to soar on its IPO day, and we saw this recently with names such as Cerebras Systems surging 68% on its debut last month and biotech Parabilis Medicines advancing 58% during its first trading day last week. So now, the natural question is: How will SpaceX stock perform in the weeks and months to come? A look at history suggests where the stock price might be in three months...
Image source: Getty Images.
The SpaceX excitement First, let's talk a bit about SpaceX and why it's generated so much excitement. SpaceX is led by Elon Musk, who is also the chief of Tesla, and at both companies, Musk is known for his big ambitions and innovations -- for example, at SpaceX, he aims to put data centers in space. Though Musk's roadmap doesn't please everyone, certain major investors, such as Ark Invest and Baron Capital, are supporters and have backed SpaceX since its earlier days.
SpaceX focuses on three businesses: rocket launches, satellite-based connectivity, and artificial intelligence (AI). Today, Starlink, the connectivity service, is the growth engine, generating $4.4 billion in income from operations last year, for a 120% gain year over year. And what's particularly interesting is SpaceX's strengths in rocket launches can serve all of its businesses, as goals across each rely on delivering certain types of equipment to space -- the fact that SpaceX can do this on its own is a big plus, as it offers the company flexibility, control, and a better cost structure.
Musk said on a livestream before the IPO that the company is heading into "a significant growth phase," according to CNBC. One of the plans is to send 100,000 satellites into space for communications.
Today's Change
(
19.22
%) $
25.95
Current Price
$
160.95
Hefty investments required All of this is exciting, and if Musk reaches some of his goals, the company may be extremely successful. But it's important to note that these projects involve a good deal of risk, too. This is because they require hefty investment, and we can't be sure that certain goals, which depend on new or not yet fully developed technology, will be reached.
Last year, capital spending in the AI business was particularly high, reaching $12 billion, and overall, SpaceX delivered an annual loss of $4.9 billion. Considering Musk's growth ambitions, I would expect this heavy investment to continue. So, while SpaceX could offer enormous rewards down the road, risk remains high.
Now let's talk about stock performance and what may happen next. A look back in time at other big IPOs can offer us some clues. SpaceX's first-day gain is actually in line with the average first-day return of IPOs from 1990 through last year. An IPO report from the University of Florida's Jay Ritter shows the average gain at 21.6%.
10 big IPOs And a look at 10 of the biggest U.S. IPOs from 1999 through 2023 offers us a clear performance pattern. Eight out of the 10 delivered a decline in the three-month period following their market debuts. And the average drop was about 13%. For example, Meta Platforms slid 50% in its first three months of trading, while Uber Technologies lost 4%.
All of this suggests that, if SpaceX follows the pattern of other enormous IPOs, the stock price could fall over the coming three months. In fact, if it's in line with the average, it could drop to $139, a level that's only slightly above its IPO price.
Though it's impossible to predict near-term stock performance with 100% certainty, history suggests that SpaceX, like other enormous IPOs before it, may not result in immediate gains for investors. All of that means, if you're intrigued by SpaceX, you don't have to rush to get in on the stock -- it's likely there will be additional buying opportunities down the road.
Scottish Mortgage Trust share price jumped by over 1% on Friday, paring back some of the losses made earlier that week as investors cheered the SpaceX IPO, which marked a major milestone for the fund. It jumped to a high of 1,497p before paring back the gains to close at 1,450p. SMT stock now faces a major headwind, but the upcoming Anthropic IPO may offer a reprief.
The SMT stock has embarked on a strong rally earlier this year as investors cheered the growing valuation of SpaceX, its biggest investment. SpaceX launched its IPO on Friday, raising $75 billion and attaining a $2.1 trillion valuation.
This means that Scottish Mortgage has a substantial return as it invested in the company when it was valued at less than $100 billion. It invested 315 million pounds in the company in 2018, a figure that has now surged.
Still, the trust faces a major risk based on how companies behave when they go public. Data shows that over 90% of all companies that went public since January 2025 made a similar pattern. They surged initially amid the IPO hype and then retreated sharply after that.
There are several good examples of this, including Figma, Circle, and Medline. Figma stock price jumped from $33 to $142, before crashing to below $20 today. Circle jumped to $300 and then crashed to $49 a few months later. Medline rose to $50 and then tumbled to $36 today.
Therefore, there is a likelihood that the SPCX stock will retreat in the coming days as investors book profits and valuation concerns remain. If this happens, the value of Scottish Mortgage’s investment will drop substantially.
Some key companies in Scottish Mortgage’s portfolio have lost momentum this year. Meta Platforms has sunk by 30% from its highest point last year, while Amazon has dropped by 14% from the YTD high.
Still, on the positive side, the SMT share price will receive a reprieve because of its stake in Anthropic, the creator of Claude. Bailie Gifford, which runs SMT, made its first investment in Anthropic in 2021 and has steadily grown its position. Anthropic now accounts for about 2.7% of its holdings.
The fund’s return has been strong as Anthropic recently raised capital at a $900 billion valuation. This fundraising makes it the fastest-growing company to cross that valuation.
Anthropic recently filed its IPO papers, with traders anticipating that it will receive a $1.5 trillion valuation after going public later this year.
The company’s other potential catalysts are its investments in Stripe and Bytedance, the parent company of TikTok. Stripe has become a major player in the finance industry, where it is used by some of the biggest companies in the world like OpenAI, Amazon, Nvidia, Ford, Coinbase, and Google.
It processes transactions worth trillions of dollars a year, with its valuation soaring to over $150 billion. After remaining private for years, Stripe will likely go public in the near future.
ByteDance will also likely go public, a move that will see it attract hundreds of billions of dollars in value.
The daily chart shows that the Scottish Mortgage share price has slipped in the past few days. It retreated from a high of 1,565p earlier this month to a low of 1,395p. It then rebounded to the current 1,450p.
The stock has formed a doji candlestick pattern, pointing to a reversal as the SpaceX IPO hype starts to fade. If this happens, the stock will drop to about 1,300p before resuming the uptrend.
SpaceX shares jumped in premarket trading on Monday following its record-breaking debut last week on the Nasdaq, which marked the biggest initial public offering in history.
Shares of SpaceX were around 6% higher at the start of premarket trading, hovering around the $170 mark.
SpaceX jumped 19% on Friday with the stock closing at $161 after being priced at $135 per share. That put the company's market capitalization above $2 trillion.
Elon Musk's space company operates the Starlink satellite internet service and a fleet of reusable rockets. In February, Musk merged the company with his artificial intelligence startup xAI. SpaceX lost nearly $5 billion in 2025 and the blockbuster IPO has sparked debate over whether the company's huge valuation is justified.
Valuation a key concernCFRA on Friday initiated coverage of the stock with a "sell" rating and a 12-month price target of $115, which is a nearly 29% drop from Friday's closing price. CFRA said its view was "due to the company's extremely ambitious growth strategy, elevated valuation expectations, and significant capital intensity."
SpaceX's capital expenditures in the three months ended March totaled $10.1 billion versus $4.1 billion in the same period last year. The majority of that went toward artificial intelligence.
Morningstar analyst Nicolas Owens released a note on June 8, in which he said the firm values SpaceX at $63 per share, and described the stock as "overvalued."
However, other analysts are more bullish. New Street Research initiated coverage of SpaceX with a $165 price target.
Item 1 of 2 A Tesla robotaxi drives on the street along South Congress Avenue in Austin, Texas, U.S., June 22, 2025. REUTERS/Joel Angel Juarez/File Photo To Match Special Report TESLA-FSD/SAFETY
[1/2]A Tesla robotaxi drives on the street along South Congress Avenue in Austin, Texas, U.S., June 22, 2025. REUTERS/Joel Angel Juarez/File Photo To Match Special Report TESLA-FSD/SAFETY Purchase Licensing Rights, opens new tab
SummaryCompaniesTesla used dubious safety stats to make case for FSD approval in EuropeAutomaker's crash data has been called into question by researchersSweden says regulators 'look beyond headline figures' to assess safetyJune 15 (Reuters) - In its efforts to secure European approval of its “Full Self-Driving” (FSD) system, Tesla (TSLA.O), opens new tab has presented self-published safety statistics to regulators in Sweden and the Netherlands that independent traffic-safety researchers have said amount to misleading marketing.
A Reuters examinationpublished last month found that Tesla CEO Elon Musk and other leaders over the past year have increasingly cited statistics they say prove its FSD driver-assistance feature is up to 10 times safer than human drivers. But the news agency’s review found several invalid data comparisons underlying Tesla’s statistics, opens new tab that exaggerated its safety claims.
The Reuters Daily Briefing newsletter provides all the news you need to start your day. Sign up here.
Tesla has presented the inflated safety data to some European regulators, according to correspondence obtained by Reuters through public records requests, as the EV maker seeks wider approval of FSD in a region where it is trying to regain market share. Tesla approached RDW, the Dutch road regulator, in late 2024 to begin the FSD approval process.
In a November 2024 letter to RDW, Tesla provided a link to its safety report and claimed “increased usage” of FSD “leads to safer roads.” Tesla charges a monthly subscription for FSD, which can drive itself under certain circumstances but requires the human driver to pay attention.
After more than a year of testing and discussions with Tesla, RDW in April approved FSD for use in the Netherlands. The Dutch regulator is now seeking EU-wide approval on behalf of Tesla.
RDW declined to comment on the issues Reuters identified with Tesla's safety statistics, but the agency said in a statement that it "does not rely on marketing claims or external statistics" to make decisions and performs its own "tests, analyses and verifications" of the system on public roads and test tracks. The agency did not say whether it assessed Tesla's U.S. safety statistics.
RDW said Tesla “collected a lot of data” during testing and the agency “validated, tested and audited all of this data.” RDW did not say what kind of data Tesla collected or what it measured.
Tesla did not respond to requests for comment.
SAVING 32,000 LIVES?Soon after the Dutch announced the decision on April 10, a Tesla policy manager, Ivan Komusanac, wrote an email to Swedish regulators asking for similar FSD approval. He attached a slide presentation displaying the exaggerated claim that Teslas using FSD can travel more than seven times farther between crashes than the average U.S. human driver.
The presentation also claimed FSD could have potentially saved 32,000 lives and prevented 1.9 million injuries.
Researchers interviewed by Reuters said those figures are highly misleading because they are based on the unrealistic assumption that every U.S. vehicle, including freight trucks and crash-prone motorcycles, would be replaced by an FSD-enabled Tesla car – and that every Tesla car is, in fact, at least seven times safer than the one it replaces.
The Reuters examination also found Tesla exaggerates the technology’s safety by comparing a rate of crashes in FSD-piloted Teslas that triggered airbag deployments to a U.S. crash rate for all vehicles that includes far less-severe accidents. The company also compares its cars to the average U.S. vehicle – which is much older than the average Tesla. That distorts the results because automakers have gradually introduced new safety features that reduce crashes.
Anders Eriksson, an investigator at the Swedish Transport Agency, declined to comment on the data Tesla provided, but added that Swedish regulators “look beyond headline figures” and that any assessment of such a system would not be based “solely on aggregated safety claims, but on the overall evidence presented.”
The regulator did not answer Reuters’ questions about what other evidence Tesla provided.
Dudley Curtis, a spokesperson for the watchdog group European Transport Safety Council, said his organization is “certainly concerned” that Tesla presented “unreliable safety data” from the United States to regulators in Sweden, after Reuters told the group about the correspondence.
He added that if Tesla wants to make safety claims, they should “give the data to a university, have it independently verified by a qualified researcher, and then let’s talk.”
TESLA LOOKS TO FSD FOR EUROPEAN REBOUNDTesla has said FSD approval in Europe is key to vehicle sales growth in the region. The EV maker is still trying to regain market share after sales plummeted last year amid protests over Musk’s political activities, including his embrace of far-right European political parties.
Failing to secure approval could make it harder for Tesla to compete in a region where Chinese EV makers are steadily making inroads.
In the coming months, representatives of 55% of member states that make up 65% of the bloc's population must vote “yes” for FSD to become legal throughout the EU.
In the meantime, individual member states can approve the technology on their own. A regulator in Greece, which said last month the country aims to approve FSD, cited data “from the other side of the Atlantic” that showed “this system ultimately leads to a very significant drop in accidents.”
The Greek transport ministry declined to answer questions about whether the data it cited was from Tesla’s safety report.
Regulators in other European countries have been inundated by drivers citing Tesla’s safety statistics and urging swift approval of FSD, emails showed.
Several Tesla drivers wrote to Norwegian road regulators citing Tesla’s vehicle safety report last autumn. One argued the technology is “significantly safer than average manual driving,” with the potential to “reduce traffic accidents by up to 90% and thus save lives on Norwegian roads.”
Stein-Helge Mundal of the Norwegian Public Roads Administration responded to several Tesla enthusiasts, saying Tesla’s figures “are self-produced,” which makes it “difficult to find correlation with the authorities’ accident statistics.”
Reporting by Chris Kirkham in Los Angeles and Marie Mannes in Stockholm; Additional reporting by Toby Sterling in Amsterdam; Editing by Mike Colias and Anna Driver
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Chris Kirkham is a business reporter in Los Angeles who writes about Tesla, electric vehicles and the wider automotive industry. He previously worked at The Wall Street Journal and the Los Angeles Times, and has covered topics including tobacco, worker safety, gambling, and the economy over a two-decade career. Contact him at [email protected] or on Signal at chris_kirkham.51
Stockholm-based company news correspondent who mainly covers anything to do with retail and industrial companies in Sweden as well as other sectors with Swedish companies. She previously covered the general Nordic stock market from Gdansk, reporting on a range of subjects, from companies exiting Russia to M&As and supply chain concerns. Marie has degrees in journalism and international relations and is keen on finding stories that drive the market and that have unreported elements to it.
A collaboration between PYMNTS Intelligence and Visa Direct, “The Power of Now: Moving At The Speed Of Life: Why Real-Time Payments Matter For Healthcare Insurance Payouts,” examines why healthcare insurance payouts remain slower than many consumers expect, even after insurance has approved a claim. The report shows that the last step in the claims process, getting money to the member, is often still tied to legacy payout methods such as paper checks and ACH transfers. That creates delays, complaints, errors and compliance concerns for insurers.
The report finds that healthcare insurance has a two-speed payout system. Core claims, such as reimbursements and coordination-of-benefits refunds, remain heavily dependent on traditional rails. More than nine in 10 insurers use ACH for core claims, and nearly as many still use paper checks. By contrast, non-claims payouts, such as wellness incentives, settlements and medical loss ratio rebates, are more likely to use faster options. That gap shows that many insurers already have access to real-time payment capabilities, but those capabilities have not yet reached the claims workflows members may care about most.
Payment processors play a major role in determining payout speed. Most insurers rely partly on outside processors for member payouts, and only about one-quarter of those insurers fully control which payment methods those processors use. That means the path to faster healthcare payouts depends not only on insurer investment, but also on whether processors can support easy-to-integrate real-time options.
The stakes are operational, financial and regulatory. Healthcare insurers report frequent friction, including consumer complaints about payment status, rejected payments, incorrect bank details and late-arriving funds. Larger insurers face especially high compliance exposure when payouts are delayed. Still, the industry is moving. Many insurers are investing in system integration, fraud prevention, verification and automation to support faster member payouts.
Download the Playbook Moving At The Speed Of Life: Why Real-Time Payments Matter For Healthcare Insurance Payouts
In “Moving At The Speed Of Life: Why Real-Time Payments Matter For Healthcare Insurance Payouts,” learn how: Healthcare insurers are using real-time payments more often for non-claims payouts than for core claims. This creates a gap between what healthcare insurers can do and how members often receive claims money. Payment processors shape the speed and choice of healthcare insurance payouts. Their capabilities can determine whether faster payment options reach members. Delayed payouts create more than a customer service problem. They can raise compliance risk, increase rework and make payment operations harder to manage. About the Report PYMNTS Intelligence surveyed 120 U.S. healthcare insurance executives between December 2025 and January 2026 for this study. All respondents hold in-depth knowledge of and decision-making responsibility for the ways their organizations issue payouts to individual members.
Respondents represent healthcare insurance carriers and providers across three annual-revenue tiers: under $100 million, $100 million to under $1 billion and $1 billion or more. The survey measured payout methods, speed of delivery, operational friction, consequences of delayed payments, barriers to real-time payout adoption, forward-looking investment plans and anticipated impacts of real-time capabilities.
See More In: featured insights, Healthcare, instant payments, Main Feature, News, Payments Intelligence, PYMNTS Intelligence, PYMNTS News, PYMNTS Study, real time payments, Visa
Here are three stocks with buy rank and strong income characteristics for investors to consider today, June 15:
Douglas Dynamics, Inc. (PLOW - Free Report) : This commercial vehicle equipment company witnessed the Zacks Consensus Estimate for its current year earnings increasing 15.4% the last 60 days.
This Zacks Rank #1 company has a dividend yield of 2.5%, compared with the industry average of 0.0%.
Luxfer Holdings PLC (LXFR - Free Report) : This materials and industrial component company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 7.1% the last 60 days.
This Zacks Rank #1 company has a dividend yield of 2.9%, compared with the industry average of 0.0%.
Starbucks Corporation (SBUX - Free Report) : This coffee company has witnessed the Zacks Consensus Estimate for its current year earnings increasing 4.4% in the last 60 days.
This Zacks Rank #1 company has a dividend yield of 2.4%, compared with the industry average of 0.0%.
See the full list of top ranked stocks here.
Find more top income stocks with some of our great premium screens.
Integration with Venmo on The Knot’s Wedding Registry gives guests a familiar and trusted way to contribute to registry cash funds, while keeping registry tracking all in one place
NEW YORK--(BUSINESS WIRE)--Today, The Knot Worldwide (TKWW), a leading global wedding technology platform and marketplace, announced Venmo, a money movement app for the next generation, is now a payment option within The Knot’s Wedding Registry. This provides a free and trusted way for users to send money from their bank, debit card, or Venmo balance for registry cash fund gifting. The new offering gives wedding guests a familiar and trusted way to contribute to couples' cash funds, while also giving couples more flexibility and control over how they receive gifts.
About 89% of couples surveyed by The Knot this year say that when it comes to cash funds, couples care the most about the ease of use for their guests. In addition, 68% of couples want to be able to track all of their gifts in one place. With Venmo now available on The Knot’s Wedding Registry, both are easy to achieve as couples can receive funds directly with Venmo.
"Venmo is widely used and trusted by more than 100 million customers worldwide, making it easy for guests to contribute in a way that feels familiar and seamless," says Anu Penmetcha, Chief Product and Experience Officer, The Knot Worldwide. "By integrating Venmo into The Knot Wedding Registry, we're removing friction from the gifting experience and helping couples maximize their funds. The Knot Wedding Registry is bringing together trusted payment options and intuitive tracking in one place, empowering couples to get the most out of every gift, from the people who matter most."
“Venmo has always been part of how people share and celebrate together, and The Knot Worldwide has long set the standard for the wedding industry,” said Alexis Sowa, General Manager, Venmo. “Together we’re enhancing the gifting experience by delivering a secure, intuitive solution that meets couples and guests where they already are.”
When guests receive cash funds in their Venmo, they now have easy access to online, in-store, and in-app merchants to easily pay with Venmo. The new feature is launching today and is available exclusively in The Knot’s app, available on the App Store for iOS or on Google Play for Android devices.
About The Knot Worldwide
Across North America, Europe, Latin America, and Asia, The Knot Worldwide champions the power of celebration. The company’s global family of brands provides best-in-class products, services, and content to take celebration planning from inspiration to action. Through its wedding brands, including The Knot, WeddingWire, Bodas.net, Hitched.co.uk, Mariages.net, Matrimonio.com, and others, the company offers an extensive database of hundreds of thousands of wedding professionals to assist couples in organizing the happiest day of their lives. We have a brand for every kind of celebration—from booking a birthday party, to planning a wedding, to preparing to become a parent, and every moment in between.
About Venmo
Venmo is the go-to money movement app of the next generation, offering fast, safe, and social payments. With best-in-class experiences for users to send, split, shop, and sell, Venmo enables a seamless flow of money between the people and places that matter most to millions of users across the United States. For more information, go to: Venmo.com.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Past performance is not an indicator of future performance. This post is illustrative and educational and is not a specific offer of products or services or financial advice. Information in this article is not an offer to buy or sell, or a solicitation of any offer to buy or sell the securities mentioned herein. Information presented is believed to be factual and up-to-date, but we do not guarantee its accuracy, and it should not be regarded as a complete analysis of the subjects discussed. Expressions of opinion reflect the judgment of the authors as of the date of publication and are subject to change.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
SummaryOracle is upgraded to Strong Buy, as I believe the market underestimates its AI-driven growth and cloud momentum.ORCL posted stellar earnings, with 47% cloud revenue growth and a 93% surge in cloud infrastructure, despite a post-earnings sell-off.Oracle's $638B RPO, disciplined cost structure, and premium margins support a rerating case, even as execution risks and leverage warrant monitoring.At 23x forward P/E and a 0.80 PEG, ORCL trades at a discount to peers despite superior top and bottom line growth. J Studios/DigitalVision via Getty Images
Well, my bull case for Oracle (ORCL) isn't playing out the way I thought it would. But I have already pointed out in my previous coverage that it may take some time
1.87K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in ORCL over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
DaVita Inc. (DVA - Free Report) : This kidney dialysis company has a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 6.4% over the last 60 days.
DaVita Inc. has a PEG ratio of 0.65 compared with 2.13 for the industry. The company possesses a Growth Score of B.
Five Below, Inc. (FIVE - Free Report) : This specialty retail company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 8.1% over the last 60 days.
Five Below has a PEG ratio of 1.09 compared with 2.01 for the industry. The company possesses a Growth Score of A.
Pitney Bowes Inc. (PBI - Free Report) : This shipping and mailing services company carries a Zacks Rank #1, and has witnessed the Zacks Consensus Estimate for its current year earnings increasing 11% over the last 60 days.
Pitney Bowes has a PEG ratio of 0.75 compared with 0.86 for the industry. The company possesses a Growth Score of A.
See the full list of top ranked stocks here.
Learn more about the Growth score and how it is calculated here.
Roku (ROKU) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Roblox Corporation ("Roblox" or "the Company") (NYSE: RBLX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between October 30, 2025 and April 30, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before August 7, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Roblox assured investors that it could minimize risks associated with age verification and accurately forecast its business performance. The Company claimed to be "enormously bullish" and able to rely on "tremendous organic growth." The Company relied on viral events to supply growth while misleading shareholders about how age verification would impact platform engagement and the public's view of its products. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Roblox, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
Crude oil settling near $95 a barrel after touching almost $115 in early April has handed the market a cleaner rotation setup than anything tech has offered in months. The IBD Stock Market Today host made the call directly: with USO breaking its 10-week moving average and the 10-year Treasury yield retreating from mid-May highs, conditions favor travel, materials, and infrastructure plays that have lagged the AI trade.
I have followed enough rotation calls to know most fade inside a week. This one has the weight behind it.
Jets Catch a Bid as Fuel Costs Cool The U.S. Global Jets ETF (NYSEARCA:JETS) closed Friday near $30, up almost 6% for the week and 13% over the past month. The host said: “A lot of times these travel stocks do much better when oil starts coming in. And this is not a bad setup. It had a good week, up over 5% for this week.” JETS also found support at its 40-week moving average, which technicians read as a credible base.
Jet fuel is the second-largest cost item for airlines after labor. Every $10 drop in crude flows directly into operating margin. With WTI down 4% for the month and the 12-month average sitting near $73, carriers have room either to expand earnings or to hold fares and grab share.
Materials Break the Downtrend The Materials Select Sector SPDR (NYSEARCA:XLB) rose 2% Friday and 3% for the week to near $52. The host flagged the chart: “Are we crossing that downtrend? And it certainly looks the case in XLB.” Three names inside XLB matter most to this story.
Linde (NASDAQ:LIN | LIN Price Prediction), the industrial gases giant, trades near $523 with Q1 2026 EPS of $4.33 and a fresh dividend bump to $1.60 quarterly from $1.50 last year. Linde returned $1.545 billion to shareholders in Q1 alone and guided FY 2026 EPS to $17.60 to $17.90.
Nucor (NYSE:NUE) is the steel story. Shares trade at $266, up 64% year-to-date and 128% over twelve months. Q1 2026 revenue rose 21% to $9.50 billion, EPS came in at 3.23, beating the 2.82 estimate, and the company authorized a $4.0 billion buyback in February. Nucor just paid its 212th consecutive quarterly dividend and notched its 53rd straight year of increases.
Freeport-McMoRan (NYSE:FCX) hands investors copper and gold exposure into the electrification buildout. The stock rallied 8% on the week to almost $68, with Q1 2026 revenue up 12% to $6.23 billion. The dividend stays at $0.15 quarterly (half base, half variable), and $2.9 billion remains on the $5.0 billion buyback authorization.
Infrastructure Where the Backlog Tells the Story The Global X U.S. Infrastructure Development ETF (NYSEARCA:PAVE) closed near $58, up 21% year-to-date. PAVE’s deliberate diversification keeps any single holding under 4% of net assets, so the story is the basket.
The flagship name is Quanta Services (NYSE:PWR). The electric grid services contractor printed Q1 2026 EPS of 2.68, beating the 2.03 estimate, revenue jumped 26% to $7.87 billion, and the backlog hit a record $48.5 billion. Management guided FY 2026 adjusted EPS to $13.55 to $14.25. Shares trade at $707, up 68% YTD, though the stock is down 9% over the past month, the only soft spot in this group.
Rates Cooperate, Too The 10-year Treasury yield sits at 4.45%, down from a mid-May high of 4.67%. That move matters more than the oil drop for capital-intensive names. Quanta, Nucor, and Freeport all carry leverage to project economics that improve when long rates ease.
What I Am Watching Three things keep this rotation alive or kill it.
WTI under $100. Anything north of $100 flips airlines back to defense and erases the JETS thesis. The 10-year staying below the May peak. A retest of 4.67% pressures every name in PAVE and XLB through discount-rate math. Spot prices in copper and steel. FCX and NUE need commodity pricing to validate the equity move, otherwise the rally is rotation in search of fundamentals. The cleanest expression here is the ETF route: JETS for the fuel-cost reversal, XLB for the materials trend break, PAVE for the multi-year grid buildout. The names inside are the ones doing the heavy lifting, and they are where the next leg of this trade will be won or lost.
The Kroger Co. (NYSE:KR) will release its first quarter earnings report before the opening bell on Thursday, June 18.
Analysts expect the Cincinnati, Ohio-based grocer to report quarterly earnings of $1.59 per share, up from $1.49 per share in the year-ago period. The consensus estimate for Kroger’s quarterly revenue is $45.49 billion. It reported $45.12 billion last year, according to Benzinga Pro.
On May 26, Kroger announced the retirement of Tim Massa, executive vice president and chief associate experience officer.
Kroger shares fell 0.6% to close at $51.26 on Friday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate analysts have rated the company in the recent period.
Considering buying KR stock? Here’s what analysts think:
Photo via Shutterstock
Market News and Data brought to you by Benzinga APIs
Q1: 2026-06-09 Earnings SummaryEPS of $0.07 beats by $0.04
|
Revenue of
$696.35M
(1.37% Y/Y)
misses by $467.04K
Designer Brands Inc. (DBI) Q4 2025 Earnings Call March 26, 2026 8:30 AM EDT
Company Participants
Matthew Crummy - Senior Vice President of Strategy and FP&A
Douglas Howe - CEO & Director
Sheamus Toal - CFO, Executive VP & Principal Financial Officer
Conference Call Participants
Mauricio Serna Vega - UBS Investment Bank, Research Division
Dana Telsey - Telsey Advisory Group LLC
Presentation
Operator
Good day, and welcome to the Designer Brands Inc., 4Q '25 Earnings Conference Call. [Operator Instructions] Please note today's event is being recorded.
I would now like to turn the conference over to Matthew Crummy, SVP of Strategy and FP&A. Please go ahead.
Matthew Crummy
Senior Vice President of Strategy and FP&A
Good morning. Earlier today, the company issued a press release comparing results of operations for the 13-week and 52-week periods ended January 31, 2026, to the 13-week and 52-week periods ended February 1, 2025.
Please note that the financial results that we will be referencing during the remainder of today's call excludes certain adjustments recorded under GAAP unless specified otherwise. For a complete reconciliation of GAAP to adjusted earnings, please reference our press release.
Additionally, please note that remarks made about the future expectations, plans and prospects of the company constitute forward-looking statements. Results may differ materially due to the factors listed in today's press release and the company's public filings with the SEC. Except as may be required by applicable law, the company assumes no obligation to update any forward-looking statements.
Joining us today are Doug Howe, Chief Executive Officer; and Sheamus Toal, Chief Financial Officer. I'll now turn the call over to Doug.
Douglas Howe
CEO & Director
Good morning, and thank you, everyone, for joining us today. I'm very proud that our fourth quarter and full fiscal 2025 results reflect disciplined execution and the meaningful progress we've
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Lucid Group, Inc. ("Lucid" or "the Company") (NASDAQ: LCID) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between February 25, 2026 and April 13, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 28, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Lucid's deliveries were disrupted by a supplier quality issue. The Company suffered a material impact on its business results due to this quality issue. The Company overstated the strength of manufacturing capabilities. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Lucid, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
To add Benzinga News as your preferred source on Google, click here.
Posted In:
EarningsEquitiesMarket SummaryNewsPre-Market OutlookTrading IdeasStocks To Watch
Connect With Us
About Benzinga
About UsCareersAdvertiseContact UsMarket Resources
Advanced Stock Screener ToolsOptions Trading Chain AnalysisComprehensive Earnings CalendarDividend Investor Calendar and AlertsEconomic Calendar and Market EventsIPO Calendar and New ListingsMarket Outlook and AnalysisWall Street Analyst Ratings and TargetsTrading Tools & Education
Benzinga Pro Trading PlatformOptions Trading Strategies and NewsStock Market Trading Ideas and AnalysisTechnical Analysis Charts and IndicatorsFundamental Analysis and ValuationDay Trading Guides and StrategiesLive Investor EventsPre-market Stock Analysis and NewsCryptocurrency Market Analysis and NewsRing the Bell
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Zoetis Inc. ("Zoetis" or "the Company") (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of ZTS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: January 14, 2025 to May 6, 2026
DEADLINE: July 27, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Zoetis faced challenges in multiple product lines including Librela, Apoquel, and Cytopoint. Based on these facts, Zoetis' public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zoetis Inc. ("Zoetis" or "the Company") (NYSE: ZTS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 27, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Zoetis suffered from weakening veterinarian prescription growth for its Librela medication after the FDA issued safety warnings about neurological complications in dogs. The Company's Trio product lost market share to competitors. The Company's Apoquel and Cytopoint dermatology products lost market share to newly launched competing treatments for dogs. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Zoetis, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
Listen to the audio version of this article (generated by AI).
Editor’s Note: SpaceX is finally public. And the FOMO is already building. But before you buy, Louis Navellier — who has been investing through major technology cycles for nearly five decades — wants you to ask one question: can you afford the volatility?
In today’s piece, Louis walks through three reasons he’s not buying SpaceX right now, despite believing it’s a wonderful company. It’s a masterclass in the difference between a great business and a great entry point — and a timely reminder that the best investors don’t just know what to buy. They know when.
He and TradeSmith CEO Keith Kaplan recently sat down to talk through all of it — including two free stock picks for the summer ahead. Watch the replay here.
Now here’s Louis.
In 2017, legendary billionaire investor Ron Baron made a big bet.
His firm invested in SpaceX (SPCX) when the company was valued at less than $22 billion.
Now, with SpaceX public, that bet could go down as one of the great investments in history. So, let’s give credit where credit is due.
But folks, before you think about buying SpaceX stock, you need to think about your risk tolerance and ask yourself:
How much risk can you stomach?
A billionaire like Baron can make a huge, concentrated bet on Elon Musk. He can wait years for it to pay off. He can ride the ups and downs. He can afford to be early and patient.
Most investors cannot afford to do any of those things.
And that is the real lesson I want you to think about as SpaceX begins trading.
So, let’s talk about how investors should handle SpaceX now that it is public and the three reasons why I do not recommend buying SpaceX stock right now… and a new tool that can help you time the market better and make bigger gains – so you don’t have to ride the emotional roller coaster on the way to profits.
Reason No. 1: Great Companies Make Terrible IPO Buys — Just Ask Facebook Now, let me first say that I think SpaceX is a wonderful company. Starlink makes money. SpaceX makes money. But a great company can still be a risky stock if you buy it at the wrong price, at the wrong time.
Case in point: Facebook, now known as Meta Platforms, Inc. (META).
Facebook went public on May 18, 2012. At the time, it was one of the most anticipated IPOs Wall Street had seen in years. Investors were clamoring to get in. The stock was priced at $38.
The FOMO was real. Then reality set in. By August 2012, Facebook had fallen to about $17.50. That was a loss of more than 50% from the IPO price.
Now, Facebook eventually became a tremendous long-term winner, up more than 1,300% since it first went public. But investors who chased the IPO still got taken to the woodshed.
That wasn’t some one-off case, either. Amazon.com, Inc. (AMZN) became one of the greatest stocks of all time – but it first fell more than 90% from its dot-com peak. Alphabet Inc. (GOOGL), then Google, became a monster winner – but only after testing investors’ patience with steep pullbacks.
Bottom line: Great stocks do not move in a straight line.
That is why I have a simple rule when it comes to IPOs. I usually wait at least a year before I buy.
That may sound boring when everyone is talking about a stock that could soar on its first day of trading. But I have been doing this for nearly five decades, and I have learned that the best time to buy a great company is not always the first time Wall Street lets you buy it.
When a company goes public, there is usually a lockup period for insiders. They cannot immediately sell their shares. But once that lockup expires, a lot of stock can come onto the market, creating selling pressure.
We saw something similar recently with another space-related stock, Rocket Lab Corporation (RKLB). As excitement around SpaceX picked up, a lot of Rocket Lab insiders were cashing out. So do not be surprised if some SpaceX insiders eventually sell after their lockup period expires.
Reason No. 2: You Can’t Grade What You Can’t See Yet The second reason I wait is to see the data.
After a company has been public for a year, I can calculate reward-to-risk. I can look at alpha. I can study standard deviation. And I can get four quarters of fundamentals to see whether the stock fits my eight-factor fundamental model.
In other words, I can stop guessing. My Stock Grader tool can give it a simple ranking of A to F, giving my followers and me a clear understanding of whether to buy it.
That matters with SpaceX because it’s a complex business. You have the launch business. You have Starlink. And you have other long-term projects that could eventually become very valuable – or not.
But as an investor, I want to know which part of the business is driving the growth. That is one of the main reasons I am willing to wait. Right now, SpaceX’s future as a public company is still speculative. A year from now, we should have a much clearer picture.
Reason No. 3: When You Buy SpaceX Stock, You’re Also Buying Elon Musk’s Headlines I should also add the Elon Musk factor.
I am not here to dispute the man’s genius. Elon Musk helped reinvent the auto industry. He helped restart America’s space ambitions. He built the world’s largest satellite internet network. He turned Tesla, Inc. (TSLA) into one of the most valuable companies on the planet.
That is an extraordinary record. But investors need to ask a very practical question:
Can you afford the volatility that comes with Elon Musk?
When you invest in a Musk-led company, you are not just investing in the business. You are also accepting the market’s reaction to Elon Musk himself.
We have seen that with Tesla. A single Musk headline can move billions of dollars in market value. His political comments, public battles and unpredictable behavior have all created added volatility around the stock at different times.
That does not erase what Musk has accomplished. But it does add another layer of risk.
The Smarter Trade This Summer: Here’s What to Do Instead The reality is there is still a tremendous amount of money sloshing around. When I was on Maria Bartiromo’s Fox Business show recently, she pointed out that there is about $7 trillion in cash on the sidelines.
Some of that money will naturally gravitate toward the market.
High-profile IPOs like SpaceX, Anthropic and eventually OpenAI could help pull more of that money into stocks. That is bullish for growth stocks and suggests investors still have a strong appetite for innovation.
But bullish does not mean blind, folks.
June is a seasonally strong month, helped by the annual Russell realignment. We should also have another great earnings announcement season kick off in July. But as we get into August and the first half of September, we’ve entered the seasonally weakest period for the market.
So, if we see drawdowns or stair-steps lower this summer, I will not be surprised.
Bottom line: This is still not a market where you can afford to guess or ignore your risk tolerance. You need to know what you own. You need to know what you are missing. And you need to know when to be aggressive – and when to be cautious.
That is exactly why I sat down with TradeSmith CEO Keith Kaplan earlier this week.
During our special event, we discussed why today’s market reminds me of the late 1990s, why I believe the AI boom still has much further to run and how a new AI-powered tool could help investors become more tactical as volatility picks up this summer.
It works by taking my financial analysis, and combining it with a new system developed by my friends over at TradeSmith. And then it adds a revolutionary new form of AI to give investors the best possible shot at massive, rapid-fire gains.
We also share two stock picks – absolutely free.
If you missed it, you can watch the replay right here.
I strongly encourage you to watch it as soon as you can.
, /PRNewswire/ -- Akeso, Inc. (HKEX: 9926) today announced that the first patient has been enrolled in the Phase Ib/II clinical study (AK138D1-202) evaluating its internally developed next-generation HER3 antibody-drug conjugate (ADC), AK138D1, as either monotherapy or in combination with ivonescimab for the treatment of advanced breast cancer.
HER3 is broadly expressed across various solid tumors, including breast, ovarian, colon, gastric, lung, skin, and pancreatic cancers, affecting millions of patients globally. While traditional HER3-targeted ADCs have demonstrated therapeutic potential in combination settings, their clinical utility has historically been constrained by dose-limiting toxicities.
AK138D1 is a next-generation, differentiated HER3-targeting ADC developed in-house by Akeso. Leveraging a unique, innovative design, AK138D1 is engineered to reduce uptake in normal tissues, thereby minimizing off-target toxicities and widening the therapeutic window. Furthermore, its design prevents the clustering of ADC molecules on the tumor surface, enhancing deep tissue penetration and uniform distribution to overcome the "binding site barrier". Early-stage clinical studies conducted in China and Australia have demonstrated that AK138D1 exhibits robust anti-tumor activity in solid tumors and breast cancer, coupled with an excellent safety profile, notably characterized by low hematologic toxicity and the absence of interstitial lung disease (ILD). This compelling balance of efficacy and safety overcomes common limitations of conventional ADCs, establishing a foundation for AK138D1 to be explored in diverse combination therapeutic regimens.
The AK138D1-202 study focuses on the two major breast cancer subtypes with the greatest unmet need: hormone receptor-positive, HER2-negative (HR+/HER2-) disease, which accounts for approximately 65% of all breast cancers, and triple-negative breast cancer (TNBC), which represents 10-20% of cases. The trial enrolls patients across multiple treatment lines from treatment-naïve to heavily pretreated, and includes diverse PD-L1 expression levels. Breast cancer remains the most common cancer among women worldwide, with an estimated 2.3 million new cases diagnosed annually. Substantial unmet needs persist in both first-line and later-line settings for HR+/HER2- breast cancer and TNBC.
Early data from AK138D1 studies have already shown meaningful efficacy and a strong safety profile in breast cancer. Concurrently, a Phase III study of ivonescimab-based combination therapy in first-line TNBC is ongoing. The combination of AK138D1 and ivonescimab is poised to emerge as a highly differentiated "IO2.0 + ADC2.0" therapeutic strategy for advanced breast cancer.
As IO+ADC combinations become a cornerstone of global oncology research, Akeso is strategically and efficiently building a comprehensive global portfolio of these next-generation therapies, leveraging its proprietary leadership in bispecific and multispecific antibody platforms.
On the IO front, Akeso stands as the only company globally with two approved bispecific antibodies for oncology, spearheading the advancement of IO2.0 therapies. Regarding its ADC pipeline, Akeso's development of AK146D1 (a Trop2/Nectin4 bispecific ADC) and AK138D1, among other innovations, aims to resolve the toxicity-related limitations of current ADCs and propel the field into the "ADC2.0" era.
About AK138D1
Injectable AK138D1 is a HER3-targeted antibody-drug conjugate (ADC), with a fully humanized anti-HER3 IgG1 antibody, patritumab. It is conjugated to the topoisomerase I inhibitor DXd through a cleavable linker, MC-AAA (maleimide-alanine-alanine-alanine). After binding to HER3 on tumor cells, the ADC is internalized into the tumor cells, where the linker is cleaved, releasing the membrane-permeable DXd. This leads to DNA damage and subsequent cell apoptosis. Early study results have shown that AK138D1 possesses potent biological activity and a favorable safety profile. A phase II clinical trial is currently ongoing to investigate AK138D1 combined with cadonilimab and ivonescimab in patients with solid tumors. This regimen is a critical part of Akeso's IO2.0 + ADC 2.0 combination approach.
About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.
Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, 27 candidates have advanced into clinical trials—including 15 bispecific or multispecific antibodies and bispecific ADCs—and 8 innovative drugs have reached commercial stage.
Through efficient and groundbreaking R&D, Akeso integrates premier global resources to develop transformative medicines, deliver high-quality, affordable therapeutic antibodies to patients worldwide, and generate sustained commercial and societal value as it strives to become a global leader in biopharmaceutical innovation.
Forward-Looking Statements
This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.
LONDON, June 15, 2026 (GLOBE NEWSWIRE) -- Willis, a WTW business (NASDAQ: WTW), today unveiled a new version of its Climate Diagnostic model to help risk managers better understand and respond to climate-driven volatility affecting property insurance markets.
Embedded within WTW’s Risk IQ platform, Climate Diagnostic is a climate risk technology capable of predicting the current and future impact of floods, windstorms and other material climate threats on an organisation’s assets, business activities and supply chain.
As extreme weather events become more severe and frequent, insurers worldwide are responding either by increasing the cost of property insurance or withdrawing from vulnerable regions entirely. With the costs of protection predicted to keep rising with climate risks and in some regions become increasingly unsustainable, the implications for individuals, businesses and economies will be long-lasting.
In order to help address this growing protection gap, Willis has embedded Climate Diagnostic into its broking workflows and risk engineering surveys. The enhanced analytics tool enables brokers and risk managers to identify and quantify the impact of acute climate hazards, such as extreme flooding or windstorm risk, on global assets and business interruption under the current and future climates.
Peter Carter, Head of Climate Practice at Willis, said: “The volatility and frequency of climate hazards are increasing. Embedding Climate Diagnostic in broking workflows and engineering surveys sets a new industry standard, with clients benefiting from a built-in scan of the risk against ongoing climate change volatility.”
Climate Diagnostic conducts scenario-based assessments across an organisation’s portfolio to identify current and future physical risk exposure to insurable climate-related perils, stress testing risk management and finance strategies in the short, medium and longer term. With this forward-looking approach, risk managers can incorporate safety measures into their risk transfer strategies that allow for rising climate volatility and explore alternative risk management methods, such as physical adaptation or alternative risk transfer solutions.
Climate Diagnostic also estimates the value of a portfolio exposed to levels of extreme weather risk and longer-term shifts in climate patterns. This supports the stress testing of current risk financing and risk transfer strategies amidst increasing climate volatility.
Peter Carter said: “Early sighting of assets exposed to climate-related perils gives risk managers the chance to build resilience, improving future insurability before disaster strikes.”
Key features of Climate Diagnostic include:
Interactive climatic and exposure maps to view highest risk areas - or physical asset portfolio exposures - for a selection of climate risks for given climate scenarios and time horizons, locate individual assets and identify financial exposure to each hazard.It is designed to be embedded in property broking and engineering workflows, helping clients consider climate volatility in risk management decisions.Climate Diagnostic data is scientifically sound, providing an independent forward-looking lens of insurable perils to clients. About WTW
At WTW (NASDAQ: WTW), we provide data-driven, insight-led solutions in the areas of people, risk and capital. Leveraging the global view and local expertise of our colleagues serving 140 countries and markets, we help organisations sharpen their strategy, enhance organisational resilience, motivate their workforce and maximise performance.
Working shoulder to shoulder with our clients, we uncover opportunities for sustainable success - and provide perspective that moves you.
Learn more at wtwco.com.
Media contact
Andrew Collis, +44 (0) 7932 725267 | [email protected]
Investment of more than €10 million will create up to 150 jobs and anchor MARSS headquarters in Nice
PARIS & CANBERRA, Australia--(BUSINESS WIRE)--Electro Optic Systems (EOS) (ASX: EOS) today confirmed an investment of more than €10 million to establish France as its European hub for AI-enabled counter-drone command and control (“C2”) systems.
"Establishing our European hub in France allows us to deliver counter-drone and command-and-control capability that partner nations own, produce, and sustain on their own terms."
Share The hub will be anchored by the headquarters of MARSS, the AI-enabled command-and-control specialist recently acquired by EOS, and will be located in Nice. The investment is expected to create up to 150 jobs over three years, including high value-added engineering and software development roles.
The new hub will strengthen France’s defence industrial ecosystem through sovereign technologies and build on EOS’s existing cooperation with KNDS. EOS will also explore the production of high-energy laser systems and the development of space domain capabilities for France and the wider European market.
“France is making a decisive commitment to its defence sovereignty, and EOS is proud to support that ambition,” said Dr. Andreas Schwer, Chief Executive Officer of EOS. “Establishing our European hub in France allows us to deliver counter-drone and command-and-control capability that partner nations own, produce, and sustain on their own terms. This is what genuine industrial sovereignty looks like.”
The announcement comes as European governments accelerate investment in air defence in response to the rapid proliferation of low-cost drones. EOS is one of a few specialised companies outside the United States able to offer high-energy laser weapons, and its model is built around full technology transfer and local production, allowing partner nations to manufacture and maintain capability without dependency on foreign export controls.
The France hub reinforces EOS’s growing European presence. The company has secured the first export order for a 100kW-class laser weapon system from the Netherlands, and has held advanced discussions with Germany following a visit by the German Federal Minister of Defence to EOS facilities.
EOS will exhibit at Eurosatory in Paris from 15 to 19 June 2026 in Hall 5A, Stand H335. Visitors can meet the team and experience live demonstrations of EOS’ AI-enabled command and control capability alongside displays of its kinetic and high-energy laser technologies.
ABOUT ELECTRO OPTIC SYSTEMS (ASX: EOS; OTC: EOPSY)
EOS operates in two divisions – Defence Systems and Space Systems:
EOS Defence Systems specialises in technology for weapon systems optimisation and integration, as well as ISR (Intelligence, Surveillance and Reconnaissance) and C4 systems for land warfare. Its key products offered include next-generation remote weapon systems, vehicle turrets, high-energy laser weapons (directed energy), as well as fully integrated and modular counter-UAS and C2 and C4 systems. C2 Systems include Command and Control Systems such as MARSS’ software-led counter-drone and critical infrastructure protection capabilities, centred on the NiDAR platform. EOS Space Systems Space Systems specialises in applying EOS-developed optical sensors and effectors to detect, track and characterise objects in space. It includes capabilities in the domain of space control. Website: https://www.eos-aus.com/
About MARSS: An EOS Company
MARSS is a global defence technology leader specialising in counter-drone and AI-powered security and surveillance systems through NiDAR. With extensive experience spanning 20 years, including research collaboration with the EU, NATO, defence agencies, academia and industry, and installations covering the globe, MARSS is a pioneer in AI-enhanced C2 and C4i solutions.
Leveraging innovation and technology to provide the highest level of security against emerging threats, MARSS’ intuitive solutions employ integrated sensor surveillance, machine learning and open-source intelligence to protect nations, critical infrastructure, naval assets, special forces, heads of state, commercial shipping and millions of lives worldwide.
About NiDAR
NiDAR is MARSS’s AI-powered Command and Control (C2) platform, providing 360-degree situational awareness across air, surface, sub-surface and land domains. The system autonomously detects, tracks, classifies and recommends responses to asymmetric threats, integrating seamlessly with a wide range of sensors and effectors to deliver end-to-end protective solutions. With more than 60 deployments worldwide, NiDAR protects what matters most: people, critical infrastructure and assets.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Commvault Systems, Inc. ("Commvault" or "the Company") (NASDAQ: CVLT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between April 29, 2025 and January 26, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 17, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Commvault shared overwhelmingly positive statements about its ARR growth while knowing or recklessly disregarding the fact that its growth guidance failed to factor in important variables including the type of sale. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Commvault, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SummaryBank of Hawaii offers two preferred share series with distinct yield and risk profiles, favoring Series A over Series B.BOH.PR.A trades at a significant discount to par, offers a ~6.9% yield, and benefits from strong dividend coverage and potential capital appreciation.BOH.PR.B, despite a higher coupon (~8%), trades above par, faces negative convexity, and offers an inferior yield-to-call (~6.78%), slightly less than Series A's current yield.Given current interest rate dynamics and call risk, Series A preferreds present superior risk-reward for allocating to BOH preferred stock.The Series A is rated as a buy at present, possessing both standalone and relative appeal.Tom Werner/DigitalVision via Getty Images
Bank of Hawaii (BOH) preferred shares possess an attractive yield at present. The company has two issues outstanding at present, with materially different economic profiles and underlying characteristics. The older series, BOH.PR.A was
290 Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Readers are advised to fact-check thoroughly before making any investment-related decisions; this reflects the personal views of the author and should not be pursued as formal financial or investment advice in any manner. While every effort has been made to ensure accuracy, errors may exist in the data and financial projections presented. The author is not responsible for any financial gains or losses incurred from investments made based on this content.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Property and casualty (P&C) insurer Progressive (PGR +0.32%) continued to knock it out of the park in the first quarter. So, then, why has it underperformed other insurance stocks? For instance, while Progressive shares are down over 23% in the last 12 months, Allstate shares are up nearly 12%.
While revenue and earnings growth has continued, it has slowed in recent quarters. There are also lingering concerns that a softening insurance market with increased competition, relaxed underwriting standards, and lower premiums, will eventually affect quarterly results.
Image source: Getty Images.
Diving deep into Progressive's Q1 2026 results For the first quarter, Progressive reported total revenue of $22.2 billion and net income of $2.8 billion, or around $4.81 per share. Underwriting margins came in at 13.6% . The company's combined ratio, which represents the percentage of premiums spent on claims and underwriting expenses, was 86.4. For comparison, most P&C insurers have combined ratios exceeding 90.
Today's Change
(
0.32
%) $
0.65
Current Price
$
202.91
Progressive managed to deliver strong margins while continuing to grow its total number of policies in force. Over the past year, policies in force increased 9%, from 36.3 million to 39.6 million.
Yet while Progressive's underwriting margins and growth remained industry-leading, the market had a mixed at best reaction to the latest figures. Metrics like net income and total policies in force fell slightly short of forecasts.
Premium and policyholder growth also slowed down in the quarter. Progressive reported a 6% year-over-year increase in premiums written, and an 8% increased in earned premiums. During the full year 2025, these figures were at 12% and 10%, respectively.
Shares remain pricey, despite continued uncertainty Progressive is about a month away from releasing quarterly results again, but as the company also issues monthly financial reports, investors aren't completely in the dark. On May 20, Progressive released its April 2026 financial report.
In April, Progressive once again reported solid net written and earned premium growth, with these metrics rising 6% and 7%, respectively, year-over-year. Net income also increased by 10% compared to the prior year's month. However, a large increase in realized investment gains skewed results; while Progressive's profitability increased by double digits, the company's combined ratio for the month came in at 90.2, meaning underwriting margins were only 9.8%, a big decline from reported margins during Q1 2026.
As Progressive did not provide any commentary alongside these figures, the root cause of this margin drop is unclear. We do know, based on commentary from CEO Tricia Griffith in the Q1 earnings call, that Progressive appears focused on capitalizing on a softening, more competitive insurance market to "continue on our growth trajectory."
With Griffith's comments suggesting a preference for growth over margins, it makes sense sell-side earnings forecasts remain downbeat, calling for earnings of $16.40 and $16.19 per share in 2026 and 2027, respectively. Compare that to 2025, when Progressive reported earnings of $18.25 per share . As uncertainty persists, you may want to stick to the sidelines. Progressive, trading for 12 times forward earnings, continues to trade at a premium to peers like Allstate, which trades for around 9 times earnings. That's not to say it will become one of the most undervalued stocks, but a further de-rating could be in store.
PARIS--(BUSINESS WIRE)--Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Graphic Packaging Holding Company ("Graphic Packaging" or "the Company") (NYSE: GPK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between February 4, 2025 and February 2, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 6, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Graphic Packaging suffered from inventory management problems, increased costs and reduced demand. The Company downplayed the severity of these issues despite the fact they would have a material impact on its financial performance. The Company overstated the strength of its business model. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Graphic Packaging, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Graphic Packaging Holding Company ("Graphic Packaging" or "the Company") (NYSE: GPK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of GPK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: February 4, 2025 to February 2, 2026
DEADLINE: July 6, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Graphic Packaging downplayed the severity of reduced demand, higher costs, and inventory management struggles. Based on these facts, Graphic Packaging's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in SPSC over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Calix, Inc. ("Calix" or "the Company") (NYSE: CALX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between January 28, 2026 and April 21, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 27, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Calix's Q1 margins benefited from the advanced purchasing of memory components. The Company's supply of these memory components was rapidly decreasing due to these advanced orders. The Company's margin faced negative pressure based on the purchase of memory at increasing market prices. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Calix, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Calix, Inc. ("Calix" or "the Company") (NYSE: CALX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of CALX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: January 28, 2026 to April 21, 2026
DEADLINE: July 27, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Calix's Q1 performance was improved by the advanced purchase of memory modules. As the Company's supply of memory fell, it suffered from significant margin pressure due to increasing memory prices on the open market. Based on these facts, Calix's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
, /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against FS KKR Capital Corp. ("FSK" or "the Company") (NYSE: FSK) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between May 8, 2024 and February 25, 2026, inclusive (the "Class Period"), are encouraged to contact the firm before July 3, 2026.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. FSK misled investors about the effectiveness of its portfolio restructuring activities. The Company overvalued its portfolio and overstated its portfolio valuation process. The Company overstated the strength of its quarterly dividend program. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about FSK, investors suffered damages.
Join the case to recover your losses
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
, /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against FS KKR Capital Corp. ("FSK" or "the Company") (NYSE: FSK) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of FSK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: May 8, 2024 to February 25, 2026
DEADLINE: July 3, 2026
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. FSK overvalued its portfolio and misled the market about its portfolio valuation process. The Company downplayed weakness in its quarterly dividend program. Based on these facts, FSK's public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Apollo Global presents a unique asset management and insurance model, blending traditional and innovative approaches for diversified growth. I see valuation as attractive given the company's differentiated business structure and potential for scalable returns. Key risks include execution challenges and insurance-specific headwinds that could impact Apollo's growth trajectory.
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs today announced the launch of the Defiance Daily Target 2X Long SpaceX ETF (Cboe: SPCU). SPCU begins trading today at 4am ET and seeks daily investment results, before fees and expenses, equal to 200% of the daily performance of SpaceX Class A common stock (NASDAQ: SPCX).
SpaceX priced its initial public offering at $135 per share and began trading on the Nasdaq on Friday, June 12, under the ticker SPCX. At that price, the company was valued at approximately $1.77 trillion, which according to reports ranks as the largest U.S. IPO in history by debut market value.
SPCU is purpose-built for active traders seeking magnified, short-term exposure to SpaceX. The Fund obtains its exposure primarily through swap agreements and/or listed options contracts rather than by holding SpaceX shares directly, allowing traders to express a high-conviction, tactical view on SpaceX in a single exchange-listed ticker, without a margin account and without managing options positions.
SPCU joins the Defiance Daily 2X Space ETF (Cboe: SPCL), which established 2X daily leveraged exposure to SpaceX on SpaceX's IPO date. On that date, SPCL's leveraged exposure was tied exclusively to SpaceX, although the Fund will hold other investments in accordance with its investment strategy and prospectus disclosures. SPCU further expands Defiance's lineup of leveraged products linked to SpaceX.
For full fund details, the prospectus, holdings, and performance current to the most recent month-end, visit defianceetfs.com/spcu or call 833.333.9383.
The Fund is not suitable for all investors. The Fund is designed to be utilized only by knowledgeable investors who understand the potential consequences of seeking daily leveraged (2X) investment results, understand the risks associated with the use of leverage, and are willing to monitor their portfolios frequently. The Fund is not intended to be used by, and is not appropriate for, investors who do not intend to actively monitor and manage their portfolios. The Fund pursues daily leveraged investment objectives, which means it is riskier than alternatives that do not use leverage. The Fund magnifies the performance of Space Exploration Technologies Corp. (the “Underlying Security”) and is designed strictly for short-term use. For periods longer than a single day, the Fund’s performance will be the result of compounded daily returns, which is very likely to differ from 200% of the return of SpaceX over the same period. It is possible that investors could lose their entire principal within a single trading day.
An investment in the Fund is not a direct investment in SpaceX.
About Defiance ETFs
Founded in 2018, Defiance is a leading ETF issuer specializing in thematic, income, and leveraged ETFs. Our first-mover leveraged single-stock ETFs empower investors to take amplified positions in high-growth companies, providing precise leverage exposure without the need to open a margin account.
Defiance ETFs LLC is the ETF sponsor. The Fund’s investment adviser is Tidal Investments, LLC (“Tidal” or the “Adviser”).
The Fund’s investment objectives, risks, charges, and expenses must be considered carefully before investing. The prospectus and summary prospectus contain this and other important information about the investment company. Please read the prospectus and/or summary prospectus carefully before investing. Hard copies can be requested by calling 833.333.9383.
Investing involves risk. Principal loss is possible. As an ETF, the Fund may trade at a premium or discount to its net asset value (“NAV”). Shares are bought and sold at market price (not NAV) and are not individually redeemed from the Fund. Brokerage commissions and bid-ask spreads will reduce returns. A portfolio concentrated in a single theme or industry may be subject to a higher degree of risk. There is no guarantee the Fund’s strategy will be successful, and an investor may lose some or all of their investment.
Leveraged Investment Risk. The Fund seeks daily investment results that correspond to two times (2X) the performance of its underlying portfolio. The use of leverage magnifies both gains and losses. As a result, the Fund may experience significant losses over short periods of time, including the potential loss of the entire investment within a single trading day. If the Target Portfolio’s market value decreases by more than 50% on a given trading day, the Fund’s investors could lose all of their money. The Fund may also be subject to the following risks:
Daily Reset and Compounding Risk. The Fund is designed to achieve its stated investment objective on a daily basis. Due to the effects of compounding, the Fund’s returns over periods longer than one trading day will likely differ, and may differ significantly, from 200% of the performance of its underlying portfolio for the same period. This effect is more pronounced in volatile markets.
Short-Term Trading Risk. The Fund is intended for short-term trading and is not designed for long-term investment. Investors who hold shares for periods longer than a single trading day may experience returns that are substantially different from the Fund’s stated objective. The Fund requires active monitoring and management.
Compounding and Market Volatility Risk. The Fund has a daily leveraged investment objective, and the Fund’s performance for periods greater than a trading day will be the result of each day’s returns compounded over the period, which is very likely to differ from two times (200%) the Target Portfolio’s performance, before fees and expenses. The Fund will lose money if the Target Portfolio’s performance is flat over time, and it is possible that the Fund will lose money even if the Target Portfolio’s market value increases over a period longer than a single day. Due to daily rebalancing and the effects of compounding, the volatility of the Target Portfolio may affect the Fund’s return as much as, or more than, the Target Portfolio’s actual return. The impact of compounding will affect each shareholder differently depending on the period of time an investment in the Fund is held and the volatility of the Target Portfolio during that holding period.
Derivatives Risk. The Fund utilizes derivatives, including swap agreements and options contracts, to achieve its investment objective. Derivatives involve risks different from, and potentially greater than, those associated with direct investments in securities. These risks include increased volatility, imperfect correlation, liquidity constraints, valuation complexity, and the potential for losses exceeding the amount initially invested.
Counterparty Risk. The Fund is subject to counterparty risk through its use of derivatives. If a counterparty to a swap or other derivative instrument fails to meet its contractual obligations, the Fund may experience losses, delays in recovery, or reduced exposure.
Space Investing Risks. The Fund concentrates its exposure in companies involved in the space economy, including satellite communications, launch services, and space-enabled technologies. Companies involved in the design, manufacture, or launch of spacecraft, launch vehicles, or related systems face significant risks associated with launch failures, deployment malfunctions, mission delays, and cost overruns; space launches are inherently complex and costly, and failures may result in total loss of spacecraft or payloads, substantial financial losses, reputational harm, and increased regulatory scrutiny. Space-related businesses often rely on advanced, emerging, or unproven technologies and may be adversely affected by rapid technological change, engineering challenges, or competitors’ development of superior or lower-cost technologies. The space industry is subject to extensive domestic and international regulation, including licensing requirements, export controls, national security restrictions, environmental regulation, and orbital debris mitigation standards; changes in laws or regulatory interpretations may increase compliance costs, delay operations, or limit deployment of space-based systems. Many space-focused companies depend on governmental or quasi-governmental customers and contracts, and reductions in government budgets, policy changes, or contract terminations could materially affect revenues. Space-based operations are exposed to risks from orbital debris, collisions, congestion in Earth’s orbits, and space weather, any of which may damage satellites or spacecraft and result in service disruptions or complete mission failure. Many space-focused companies may have limited operating histories, depend on a narrow set of products or services, or rely on a small number of customers or missions. The Fund may have exposure to foreign issuers, including through ADRs, which can involve political instability, geopolitical tensions, trade restrictions, sanctions, and currency fluctuations that may disrupt supply chains or impair cross-border collaboration. When the Adviser determines there are insufficient Space Companies to meet the Fund’s investment criteria, the Fund may obtain exposure to secondary space technology companies that support or enable space-related activities, which may be less directly exposed to the growth of the space economy and may be more sensitive to broader industry or market risks. The space industry is emerging and may experience higher volatility and uncertainty than more established industries.
Industry Concentration Risk. Because the Fund focuses on a specific theme and industry group, it may be more susceptible to adverse developments affecting that sector than a broadly diversified fund. The Fund will concentrate (i.e., invest 25% or more of its total assets) its investment exposure to companies in the space industry and in industries that develop, deploy, or operate space-related technologies and services.
IPO, SPAC, and De-SPAC Risk. The Fund may invest, including indirectly via derivative instruments, in securities of companies that have recently completed initial public offerings (“IPOs”), special purpose acquisition companies (“SPACs”), or companies that have become publicly traded through business combinations involving SPACs (“de-SPAC transactions”). These securities may be less seasoned, lack a meaningful trading history, have limited public information and research coverage, and involve risks similar to those of venture capital or other private equity investments. Their prices may be volatile, subject to speculative trading, and susceptible to rapid and substantial declines in value. SPACs are shell or blank check companies that raise capital in an IPO for the purpose of completing a business combination with a private operating company; there is no guarantee that a SPAC will complete a business combination or that any completed transaction will be successful. Conflicts of interest may arise among a SPAC’s sponsors, affiliates, officers, directors, or promoters and unaffiliated security holders.
Swap Agreements. The use of swap transactions is a highly specialized activity, which involves investment techniques and risks different from those associated with ordinary portfolio securities transactions. Whether the Fund will be successful in using swap agreements to achieve its investment goal depends on the ability of the Adviser to structure such swap agreements in accordance with the Fund’s investment objective and to identify counterparties for those swap agreements.
Non-Diversification Risk. The Fund is classified as non-diversified, which means it may invest a larger percentage of its assets in a smaller number of issuers. As a result, the Fund’s performance may be more volatile and more sensitive to the performance of individual holdings.
Equity Securities Risk. Investments in equity securities are subject to market risk, including the potential for significant price fluctuations due to company-specific events, broader market conditions, economic developments, and changes in investor sentiment.
Foreign and ADR Risk. To the extent the Fund has exposure to foreign issuers or American Depositary Receipts (ADRs), it may be subject to additional risks, including currency fluctuations, political and economic instability, differing regulatory standards, and reduced liquidity.
Small- and Mid-Capitalization Risk. The Fund may invest in small- and mid-cap companies, which may be more volatile, less liquid, and more sensitive to economic changes than larger companies.
Liquidity Risk. In certain market conditions, the Fund’s investments or derivative instruments may become less liquid, making it difficult to adjust exposure or achieve the desired investment objective. Reduced liquidity may also lead to wider bid-ask spreads for Fund shares.
Rebalancing Risk. The Fund seeks to rebalance its exposure daily to maintain its target leverage. If the Fund is unable to rebalance effectively due to market disruptions, liquidity constraints, or operational issues, its exposure may deviate from its intended objective.
Tracking and Correlation Risk. There is no guarantee that the Fund will achieve a high degree of correlation to 200% of the daily performance of its underlying portfolio. Market volatility, fees, transaction costs, and derivative pricing may cause performance to deviate from expectations.
High Portfolio Turnover Risk. The Fund’s strategy involves frequent trading and daily rebalancing, which may result in high portfolio turnover, increased transaction costs, and potentially higher taxable distributions.
Tax Risk. The Fund intends to qualify for favorable tax treatment as a regulated investment company (RIC), but there is no guarantee it will do so. Distributions may be taxable as ordinary income, capital gains, or a combination of both.
New Fund Risk. The Fund is recently organized and has limited operating history. As a result, there is limited performance history for investors to evaluate.
Market and Economic Risk. The value of the Fund’s investments may decline due to general market conditions, economic trends, geopolitical events, interest rate changes, inflation, or other external factors beyond the control of the Fund.
Brokerage commissions may be charged on trades.
Distributed by Foreside Fund Services, LLC.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/623c9438-6e10-4373-bc05-a6ae8c312daf
SpaceX's blockbuster IPO has some analysts warning that years of aggressive growth may be already priced in. Retail investor enthusiasm could become a risk if SpaceX misses revenue or earnings expectations.
A general view of a SpaceX facility on the day of the company’s initial public offering (IPO), in Starbase, Texas, U.S., June 12, 2026. REUTERS/Gabriel V. Cardenas Purchase Licensing Rights, opens new tab
June 15 (Reuters) - Elon Musk said on Sunday that his rocket company, SpaceX (SPCX.O), opens new tab, could bring in $1 trillion in revenue by 2030, making the statement two days after the company went public, valuing it at over $2 trillion.
"And I would be surprised if revenue is not greater than $1T in 2031," he wrote on his social media platform X, replying to journalist and financial commentator Jon Erlichman.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
SpaceX on Friday became the sixth-largest U.S. firm, cementing Musk's status as the world's first trillionaire.
However, the company still makes far less money than similarly valued tech giants like Broadcom (AVGO.O), opens new tab and Amazon.com (AMZN.O), opens new tab.
In 2025, SpaceX's revenue jumped to $18.67 billion from $14.02 billion a year earlier, but the company swung to a net loss of $4.94 billion from a profit of $791 million.
Some Wall Street analysts are cautious about the company's growth.
Goldman had estimated that SpaceX's revenue would exceed $470 billion in 2030, while Morgan Stanley projected it would reach nearly $330 billion, according to a Wall Street Journal report from earlier this month.
Reporting by Shivani Tanna in Bengaluru; Editing by Nivedita Bhattacharjee
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Meta Platforms remains a top AI growth story, now trading at only 18x forward P/E after a 14% YTD decline. I reiterate a Strong Buy rating, viewing the recent sell-off as overblown given META's consistent top and bottom-line outperformance. META's robust historical earnings, double beats, and exposure to multi-year AI, data center, and digital ad growth are undervalued by the market.
Analyst’s Disclosure: I/we have a beneficial long position in the shares of UBER either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Microsoft CEO Satya Nadella compared AI's impact to the problems globalization first caused. George Chan/Getty Images AI models are hoovering up corporate knowledge, and that's leaving one big loser, says Satya Nadella.
In an article posted on X on Sunday, the Microsoft CEO warned of a future in which a handful of AI providers capture most economic value while industries lose ownership of their knowledge.
"The last thing any of us want is a world where every company across every sector is ceding value to a few models that eat everything they see," Nadella wrote. "There is no societal permission for an AI future that hollows out entire industries."
Nadella compared the AI era to globalization, warning against repeating that dynamic.
"Think about what happened in the first phase of globalization, where entire industrial economies were hollowed out by outsourcing," he wrote. "The GDP numbers looked fine on the surface, but the displacement was real and the consequences are still being felt."
Instead, he advocated for a broad AI ecosystem in which companies keep control of their learning systems, which he said would enable innovation and retain employee expertise.
Nadella's post echoed concerns other Big Tech CEOs have been raising this year.
In a February podcast, Snowflake CEO Sridhar Ramaswamy said that the biggest software companies are at risk of being reduced to mere data sources.
"The big model makers want to create a world in which all of the data for all of the enterprises is easily available to them," Ramaswamy said. "Everything else, the world, is just a dumb data pipe that feeds into that big brain."
Ramaswamy added that Snowflake needs to operate with a "fear" that people would stop using AI agents developed by software companies and instead want an all-inclusive agent that has data from Snowflake and everywhere else.
In a January LinkedIn post, Box CEO Aaron Levie said that AI models can perform high-level knowledge work across nearly every profession, from law to strategy and scientific research.
"The question that we will have to wrestle with is, in a world where everyone has access to the same expert intelligence, how does a company differentiate?" Levie wrote. He said that context would be the answer.
Read next
Shubhangi Goel You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Tyra Banks is suing Netflix. Manny Carabel/Getty Images Tyra Banks, a model and the creator of the reality TV show "America's Next Top Model," is suing Netflix.
In a 65-page lawsuit filed on Saturday, Banks' attorneys accused the streaming service of falsely portraying her in the three-part docuseries, "Reality Check: Inside America's Next Top Model."
The three-part documentary was released in February. It charted the meteoric rise of the long-running modeling reality show from its early days to its immense cultural impact. It included an interview with Banks and her onetime collaborators, like creative director Jay Manuel and runway coach J. Alexander, and featured at least 10 contestants.
Banks' attorneys filed a lawsuit against Netflix, the producers of the show Everwonder Studio, and directors Mor Loushy and Daniel Sivan. They said the docuseries cut out parts of her interview in which they said she took responsibility for some of the show's controversies.
"Of the hours of answers Ms. Banks provided, the producers used only about sixteen minutes," her team wrote in the lawsuit. "The producers used what could be stripped of context and reassembled to support a false and defamatory narrative unrelated to what she actually expressed."
The team said that Banks gave the documentary producers a three-and-a-half-hour interview and did not limit the interviewer's questions.
"The accountability Ms. Banks took ended up on the cutting room floor. It was there, but viewers were never given the opportunity to see it," they added.
Her attorneys said that the producers created a false narrative through "selective editing, deliberate omission, and surgical manipulation of continuous footage."
One of the major complaints listed in the lawsuit was that the producers interviewed season two contestant Shandi Sullivan, who told them she had viewed an incident that happened on set as sexual assault.
Banks said the producers did not disclose Sullivan's account to her before the interview, and they selectively edited her responses to make it appear that she was not willing to take accountability for the incident.
The lawsuit said that before taking legal action, the team had asked Netflix for unedited footage of Banks' interview, but Netflix denied the request. It added that Netflix did not give Banks the opportunity to respond to any allegations from other participants.
In the lawsuit, Banks' team sought damages and the removal of her face from the album cover of a 26-track soundtrack for the documentary.
Netflix, which has not yet filed a response to the lawsuit, declined to comment.
Read next
Aditi Bharade You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.
Item 1 of 2 A Walmart sign at its booth during the China International Supply Chain Expo in Beijing, China July 16, 2025. REUTERS/Florence Lo
[1/2]A Walmart sign at its booth during the China International Supply Chain Expo in Beijing, China July 16, 2025. REUTERS/Florence Lo Purchase Licensing Rights, opens new tab
CompaniesBEIJING, June 15 (Reuters) - China's market regulator has ordered strict measures by Walmart supermarket chain Sam's Club to eliminate food safety risks throughout its supply chain and safeguard public dietary safety, the regulator said.
The admonition comes amid a push to expand in China during which Sam's Club racked up double-digit growth in transactions last year as new openings boosted its tally of membership-only stores to 63 nationwide, its website shows.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
The action followed a meeting with an executive of the U.S. retailer to discuss recently detected food safety issues, the State Administration for Market Regulation said in a notice on Monday, without giving the date of the meeting.
Walmart's China office did not immediately respond to a request for comment.
"We will regularly report rectification progress to the regulatory authorities and proactively accept supervision," Sam's Club said in an apology, according to a state-backed media outlet, the Paper.
The chain has set up a special task force led by management to remedy matters, along with supply chain inspections, while offering assurances of strict compliance with rules and optimal product quality control, it added.
Reporting by Liz Lee and Beijing newsroom; Editing by Clarence Fernandez
Our Standards: The Thomson Reuters Trust Principles., opens new tab
An empty Starbucks store in Seoul, South Korea, May 26, 2026. REUTERS/Kim Hong-Ji Purchase Licensing Rights, opens new tab
SummaryCompaniesStarbucks Korea to close all stores June 22 for staff training after marketing backlashControversy stemmed from 'Tank Day' promotion coinciding with Gwangju Uprising anniversaryStarbucks Korea remains market leader with over 2,000 storesSEOUL, June 15 (Reuters) - Starbucks Korea will shut all stores in the country at 3 p.m. on June 22 for staff training on historical awareness and social sensitivity, the operator Shinsegae Group (004170.KS), opens new tab said on Monday, following public backlash over a marketing campaign.
The coffee chain faced widespread criticism and suffered a "very significant" drop in sales after last month's campaign that evoked a brutal 1980 military crackdown on pro-democracy protesters.
The Reuters Inside Track newsletter is your essential guide during the World Cup. Sign up here.
Shinsegae's affiliate E-Mart (139480.KS), opens new tab owns Starbucks Korea, which launched its 'Tank Day' tumbler promotion on the anniversary of the May 18 Gwangju Uprising, when the military government deployed troops and tanks to suppress pro-democracy demonstrations.
Starbucks Korea headquarters staff and executives from Shinsegae's E-Mart division will undergo the same training on June 17 at the group's in-house training centre, while Shinsegae Chairman Chung Yong-jin and affiliate CEOs will attend a separate session on June 24, the group said.
Shinsegae said the move reflected how seriously it viewed the recent marketing controversy and its commitment to preventing a recurrence. Chung previously apologised publicly over the controversy.
The history awareness lecture, led by a history professor from Sungkyunkwan University, will review the major events in South Korea's modern and contemporary history since the 1950s and discuss how they should be understood, it said.
A separate social sensitivity training, conducted by a sociology professor at the same university, will look at how companies should consider social issues such as history, labour, gender and human rights in marketing and other corporate activities, the company said.
The company said it would be the first nationwide early closure of Starbucks Korea stores since the chain opened in the country in 1999.
Starbucks Korea also plans to overhaul marketing approval procedures, including introducing a social-sensitivity checklist covering history, commemorative dates, politics, disasters, military issues, gender, violence and hate expressions, Shinsegae said.
Starbucks Korea had more than 2,000 stores in the country as of end-2024 according to its annual impact report. It is the country's No. 1 coffee chain in terms of customer payments, according to data firm WISEAPP.
Reporting by Joyce Lee, Jack Kim and Kyu-seok Shim Editing by Ed Davies
Our Standards: The Thomson Reuters Trust Principles., opens new tab
VENLO, Netherlands & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced new additions to its QIAcuity digital PCR (dPCR) ecosystem, with a focus on expanding gene expression capabilities, broadening assay content and enhancing workflow standardization to support the growing adoption of dPCR across life sciences and biopharma applications.
As researchers increasingly seek higher sensitivity, greater precision and improved multiplexing capabilities, dPCR is gaining adoption across a growing range of applications traditionally served by qPCR technologies. QIAGEN is expanding the QIAcuity ecosystem with new gene expression solutions, workflow automation and analysis capabilities designed to support broader adoption of digital PCR across research and biopharma applications.
"Gene expression represents one of the largest application areas in molecular biology and a significant opportunity for digital PCR," said Thierry Bernard, CEO of QIAGEN. "By expanding the QIAcuity ecosystem with new assays, enhanced multiplexing capabilities and workflow solutions, we are helping customers apply digital PCR to a broader range of research and biopharma applications."
The latest additions to the QIAcuity portfolio include:
New gene expression solutions for dPCR: QIAGEN plans to expand its portfolio later in 2026 with new QIAcuity Gene Expression Assays designed to support gene expression analysis across human, mouse and rat research applications. The company also plans to introduce the new QIAcuity OneStep High Multiplex Probe PCR Kit, enabling analysis of up to 12 RNA targets in a single reaction and helping researchers generate richer biological insights while reducing sample consumption, hands-on time and workflow complexity. These additions complement QIAGEN's GeneGlobe platform, providing access to more than 10 million predesigned assays as well as custom assay design capabilities for specialized research needs. Expanded Cell and Gene Therapy quality control portfolio: Building on its established portfolio of dPCR solutions for Cell and Gene Therapy applications, QIAGEN is expanding its residual DNA testing offering to support additional producer cell systems, including Sf9/Baculovirus, Pichia pastoris, Vero and Mouse. The portfolio also includes the recently launched QIAcuity HEK293 resDNA Sizing Kit, which enables precise measurement of both host-cell DNA concentration and fragment size distribution to support biopharmaceutical development and manufacturing workflows. Enhanced automated analysis and reporting with QIAcuity Software 3.5: Scheduled for release later this month, QIAcuity Software 3.5 introduces advanced analysis templates and automated reporting capabilities that enable users to define analysis and reporting parameters before a run begins. The software helps laboratories automate and standardize data interpretation and reporting through predefined analysis and reporting templates. By automatically applying analysis parameters and generating reports after run completion, laboratories can reduce manual review steps while improving traceability, consistency and operational efficiency, particularly in larger-scale and regulated workflows. Expanded laboratory automation through Hamilton integration: In addition to the automated analysis and reporting capabilities introduced with QIAcuity Software 3.5, customers can build on QIAGEN's collaboration with Hamilton to automate QIAcuity dPCR nanoplate setup and handling workflows, including sample preparation, nanoplate filling and sealing. Integration with robotic systems enables fully automated workflows from assay setup through data analysis, helping high-throughput laboratories increase productivity while minimizing risks associated with manual handling. QIAcuity adoption continues to grow across academia, biopharma and clinical research, with over 3,200 cumulative placements worldwide since launch. More than 400 customers now operate multiple QIAcuity instruments, while over 1,100 scientific publications reference the platform. The continued expansion of the QIAcuity ecosystem reflects QIAGEN's strategy to support customers throughout the transition from qPCR to dPCR and toward increasingly scalable, automated and standardized dPCR workflows.
Additional details on QIAGEN's QIAcuity dPCR strategy, technology roadmap and growth opportunities will be discussed during the upcoming QIAcuity Deep Dive event on Monday, June 15, 2026. The event will be webcast and available to investors, analysts and other interested stakeholders. More information is available at https://corporate.qiagen.com/English/investor-relations/events-and-presentations/QIAGEN-Deep-Dive--QIAcuity-digital-PCR/default.aspx.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Oshkosh Defense Highlights Proven, Adaptable Tactical Mobility Solutions for Europe at Eurosatory 2026 As European and allied forces accelerate modernization efforts in response to evolving operational threats, Oshkosh Defense LLC, an Oshkosh Corporation [NYSE: OSK] business, will showcase proven tactical mobility solutions at Eurosatory 2026 designed to support interoperability, distributed operations and future battlefield requirements, without the risk and long development timelines of entirely new vehicle programs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614504023/en/
Oshkosh Defense Hybrid Electric Joint Light Tactical Vehicle (eJLTV).
For decades, Oshkosh Defense has supported allied military forces with heavy, medium and light tactical vehicle platforms designed to operate across coalition environments. Today, as NATO and European partners prioritize readiness, sustainment resilience and operational flexibility, Oshkosh Defense continues to evolve its proven platforms to meet emerging mission requirements. At Eurosatory 2026, Oshkosh Defense will feature its hybrid electric Joint Light Tactical Vehicle (eJLTV), an advanced capability demonstrator built on the combat-proven JLTV platform currently fielded by the United States and allied nations worldwide. With more than 24,000 JLTVs produced, the platform provides a mature, interoperable foundation capable of adapting to future operational requirements while maintaining commonality across coalition forces. The eJLTV demonstrates how allied forces can modernize tactical mobility capabilities while reducing transition risk, leveraging existing sustainment infrastructure and preserving operational familiarity for deployed forces. The platform integrates hybrid electric capability, onboard exportable power generation, silent watch and silent drive functionality to support distributed operations, next-generation battlefield systems and evolving operational energy requirements.
By building on a fielded and combat-proven platform, Oshkosh Defense offers allied customers a scalable path toward future capability integration without sacrificing reliability, survivability or interoperability. The JLTV platform also creates opportunities for localized sustainment, long-term fleet support and regional operational integration aligned with allied modernization priorities.
“European and allied forces are modernizing under real operational pressure, and they also need solutions that can be fielded, sustained and integrated quickly,” said Pat Williams, Chief Programs Officer at Oshkosh Defense. “The eJLTV demonstrates how Oshkosh Defense can evolve a combat-proven platform to support future power, interoperability and distributed operational requirements without forcing customers to accept the risk and timelines associated with entirely new vehicle programs.”
Attendees can experience the eJLTV and learn more about Oshkosh Defense’s portfolio of advanced tactical mobility solutions and technologies at Eurosatory 2026 in Booth A320 in the USA Pavilion.
About Oshkosh Defense
Oshkosh Defense, an Oshkosh Corporation business [NYSE: OSK], delivers adaptable, connected, and survivable systems critical to the modernization and readiness of the U.S. and its allied forces. As a trusted mobility integrator, Oshkosh brings advanced vehicles, intelligent systems, and mission-critical technologies together into unified solutions built for evolving operational demands. Combining defense expertise with commercial scale, Oshkosh accelerates innovation from development through deployment. And because the mission does not end at fielding, Oshkosh provides global sustainment, lifecycle support, and aftermarket solutions that keep fleets ready while advancing the future of defense mobility.
Learn more at OshkoshDefense.com.
About Oshkosh Corporation
At Oshkosh (NYSE: OSK), we make innovative, purpose-built vehicles and equipment to help everyday heroes advance communities around the world. Headquartered in Wisconsin, Oshkosh Corporation employs over 18,000 team members worldwide, all united behind a common purpose: to make a difference in people’s lives. Oshkosh products can be found in more than 150 countries under the brands of JLG®, Pierce®, MAXIMETAL, Oshkosh® S-Series™, McNeilus®, IMT®, Jerr-Dan®, Frontline™ Communications, Oshkosh® Airport Products, Oshkosh AeroTech™, Oshkosh® Defense and Pratt Miller. For more information, visit oshkoshcorp.com.
Forward Looking Statements
This news release contains statements that the Company believes to be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including, without limitation, statements regarding the Company’s future financial position, business strategy, targets, projected sales, costs, earnings, capital expenditures, debt levels and cash flows, and plans and objectives of management for future operations, are forward-looking statements. When used in this news release, words such as “may,” “will,” “expect,” “intend,” “estimate,” “anticipate,” “believe,” “should,” “project” or “plan” or the negative thereof or variations thereon or similar terminology are generally intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, assumptions, and other factors, some of which are beyond the Company’s control, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These factors include risks related to the Company’s ability to successfully execute on its strategic road map and meet its long-term financial goals. Additional information concerning these and other factors is contained in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements speak only as of the date of this news release. The Company assumes no obligation, and disclaims any obligation, to update information contained in this news release. Investors should be aware that the Company may not update such information until the Company’s next quarterly earnings conference call, if at all.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260614504023/en/
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced pivotal Phase 2 results from Cohort 1 of the PROGRESS study evaluating zilurgisertib, an investigational oral activin receptor-like kinase 2 (ALK2) inhibitor, in adolescents and adults (≥12 years of age) with fibrodysplasia ossificans progressiva (FOP). Results were shared in a late-breaking rapid-fire presentation at ENDO 2026, the Endocrine Society’s annual meeting.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614539468/en/
Results from Cohort 1 of the PROGRESS study demonstrated a consistent treatment effect across measures of disease activity and durability through Week 48. During the open-label extension, no new HO lesions were observed among patients who continued to receive zilurgisertib or among placebo-treated patients who crossed over to active treatment at Week 24.
"The findings presented at ENDO represent an important milestone for the zilurgisertib program and further strengthen the growing body of clinical evidence supporting its potential as a treatment for FOP," said Steven Stein, M.D., Executive Vice President, Chief Medical Officer and Head of Late-Stage Development at Incyte.
"People living with FOP and their families urgently need additional treatment options," said Joanne Quan, M.D., Chief Medical Officer at Mirum Pharmaceuticals. "These results reinforce our confidence in the potential of zilurgisertib and our commitment to working with Incyte to bring this important program forward as we prepare for potential commercialization and support the FOP community."
Cohort 1 of the PROGRESS study evaluated zilurgisertib 100 mg once-daily in 63 adolescents and adults (≥12 years of age) with FOP. Patients were randomized 1:1 to receive zilurgisertib (n=32) or placebo (n=31) during a 24-week, placebo-controlled, double-blind period, followed by an open-label extension period. Baseline demographics and disease characteristics were generally balanced between treatment groups, with a mean age of approximately 21 years and evidence of recent disease activity prior to enrollment. A total of 61 patients had 48-week whole-body CT scan data available at the time of the open-label extension analysis.
Key efficacy findings included:
Fewer patients receiving zilurgisertib developed new HO lesions at Week 24, with an 81% reduction versus placebo (p=0.0986). 99.9% reduction in total volume of new HO lesions in patients receiving zilurgisertib versus placebo at Week 24 (nominal p-value<0.0001). Reduction in total existing HO lesion volume compared with an increase observed in placebo-treated patients at Week 24 (nominal p-value=0.004). Among patients receiving zilurgisertib, no new HO lesions were observed and total HO lesion volume continued to decrease from Week 24 to Week 48. Among patients who crossed over from placebo to zilurgisertib, no new HO lesions were observed and total HO lesion volume decreased from Week 24 to Week 48. Key Efficacy Findings (Week 24 Placebo-Controlled Period and Week 48 Crossover)
Endpoint
Zilurgisertib (ZGB)
(n=32)
Week 24
Placebo
(n=31)
Week 24
Key Finding
Open-Label Extension
Week 48
Number (%) of patients who developed new HO lesions
1 (3.1)
5 (16.7)
81% reduction vs placebo
No patients with new HO lesions observed at Week 48 (n=61)
Zilurgisertib was generally well-tolerated during the 24-week placebo-controlled period of the study. Data showed:
Most adverse events were mild or moderate in severity. No adverse events led to treatment discontinuation or dose reduction. Serious adverse events and Grade ≥3 adverse events occurred at low rates in both treatment groups. The most commonly reported adverse events among patients receiving zilurgisertib were FOP flare-up or aching/pain due to FOP (25%), headache (21.9%), upper respiratory tract infection (21.9%), arthralgia (18.8%), epistaxis (12.5%), and nausea (12.5%). The full abstract is available on the Endocrine Society’s ENDO 2026 website. Detailed analyses are also posted on the Publications & Presentations section of Mirum’s website.
The U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for zilurgisertib for the treatment of FOP in patients 12 years of age and older and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) target action date for zilurgisertib is September 26, 2026.
About Zilurgisertib
Zilurgisertib is an investigational, oral, small molecule, activin receptor-like kinase 2 (ALK2) inhibitor in development for the treatment of Fibrodysplasia Ossificans Progressiva (FOP). Zilurgisertib is designed to inhibit the ALK2 receptor, which is abnormally active in most patients with FOP and leads to bone formation in soft tissues, a process known as heterotopic ossification (HO). FOP is an ultra-rare genetic disease that affects approximately 300 patients in the U.S. and 900 worldwide, with diagnosis typically occurring in early childhood. Zilurgisertib was evaluated in the PROGRESS pivotal Phase 2 study, which formed the basis of a new drug application (NDA). The FDA has accepted the NDA for zilurgisertib in FOP under Priority Review with a Prescription Drug User Fee Act (PDUFA) date of September 26, 2026.
Mirum Pharmaceuticals, Inc. licensed zilurgisertib from Incyte for worldwide development and commercialization.
About the PROGRESS Study
PROGRESS is a global, randomized, double-blind, placebo-controlled Phase 2 study evaluating the efficacy and safety of zilurgisertib in patients with fibrodysplasia ossificans progressiva (FOP). PROGRESS Cohort 1 enrolled patients 12 years of age and older who were randomized 1:1 to receive zilurgisertib 100 mg once daily or placebo during a 24-week double-blind treatment period, followed by an open-label extension. Additional PROGRESS cohorts will evaluate the efficacy and safety of zilurgisertib in patients ages 6 to <12 years of age (Cohort 2) and in patients ages 2 to <12 years of age (Cohort 3).
The primary endpoint of the study is the proportion of Cohort 1 patients with new heterotopic ossification (HO) lesions at Week 24 as assessed by whole-body CT scan data. Key secondary endpoints include the number and total volume of new HO lesions, changes in total HO lesion volume and flare activity through Week 24.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals (NASDAQ: MIRM) is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).
Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).
Mirum’s success is driven by a team dedicated to advancing high impact medicines through strategic development, disciplined execution and purposeful collaboration across the rare disease ecosystem. Learn more at www.mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and X.
About Incyte®
Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation & Autoimmunity.
To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.
Mirum Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the Company’s planned participation at a scientific congress, Mirum’s continued advancement of zilurgisertib with Incyte, the likelihood of a FDA approval pathway for zilurgisertib and the potential benefit of zilurgisertib in real world settings versus scientific presentations of data. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “expected,” “will,” “could,” “would,” “guidance,” “potential,” “continue” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Mirum’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Mirum’s business in general, the impact of geopolitical and macroeconomic events, and the other risks described in Mirum’s Annual Report for the year ended December 31, 2025, filed with the Securities and Exchange Commission on February 25, 2026, and subsequent filings with the Securities and Exchange Commission, which are available at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Mirum undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Incyte Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the presentation of data from the PROGRESS study; the potential for zilurgisertib to become a treatment option for people living with FOP; expectations regarding ongoing and future clinical trials for zilurgisertib, including the timing of such trials; and Incyte’s aspirations and goals as set forth under the heading “About Incyte.”
Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including the sufficiency of clinical trial data to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; the efficacy or safety of Incyte’s and its partners’ products; the ability of Incyte and its partners to achieve commercial success for their marketed products and product candidates, if approved; Incyte’s and its partners’ ability to obtain and maintain protection of intellectual property for their products and technology; Incyte’s reliance on third parties and partners; the acceptance of Incyte’s and its partners’ products in the marketplace; market competition, sales, marketing, manufacturing and distribution requirements; greater than expected expenses, including expenses relating to litigation or strategic activities; and those risks and uncertainties discussed in greater detail in Incyte’s reports filed with the U.S. Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2025, and its quarterly report on Form 10-Q for the quarter ended March 31, 2026. Incyte disclaims any intent or obligation to update these forward-looking statements.
Mirum and the Mirum logo are trademarks of Mirum Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260614539468/en/
